IDP-Inspired Nanovectors for Direct Cytosolic mRNA Delivery: Technical Advances and Implications

Study Background and Research Question

Intracellular delivery of large, functional biomacromolecules—such as mRNAs, proteins, and gene editing complexes—remains a major challenge in molecular biology and translational research. Conventional approaches often rely on vesicular transport, endosomal escape, or synthetic vectors, each with inherent limitations in efficiency, stability, and cytosolic release. Membraneless organelles (MLOs), naturally formed through liquid-liquid phase separation (LLPS) of intrinsically disordered proteins (IDPs), provide a biological precedent for energy-efficient, reversible, and selective partitioning of macromolecules within the cell. However, engineering synthetic systems that recapitulate the conformational adaptability and robust delivery capabilities of MLOs has proven difficult. The central research question addressed in Jin et al., 2025 is whether nanovectors inspired by the structure and phase behavior of IDPs can be rationally designed to form stable nanocoacervates (NCs) for direct and efficient cytosolic delivery of diverse biomacromolecules under physiological conditions.

Key Innovation from the Reference Study

The pivotal advance of this study is the development of IDP-inspired nanovectors (IDP-NVs) engineered to possess conformational flexibility analogous to biological IDPs. These nanovectors can form coacervate complexes with a broad range of cargoes—including mRNA, proteins, and ribonucleoproteins—via multivalent, cooperative interactions. The resulting nanocoacervates not only maintain stability in physiological environments but also exhibit a unique ability to traverse cellular membranes directly, bypassing endosomal entrapment. Upon cytosolic entry, intracellular glutathione mediates disassembly of the NCs, resulting in efficient release of the encapsulated functional biomacromolecules.

Methods and Experimental Design Insights

Jin et al. designed the IDP-NVs with two essential modules: a flexible 'sticker' domain responsible for dynamic interactions and a 'spacer' segment that modulates spatial orientation. The study used a systematic approach to characterize the phase separation, coacervate formation, and stability of these nanovectors in the presence of various biomacromolecules. Key experimental techniques included:

• Dynamic light scattering and transmission electron microscopy to assess nanocoacervate size, morphology, and dispersity under physiological salt and pH.
• Fluorescence microscopy and flow cytometry to monitor cellular uptake and cytosolic localization of both the nanovectors and their cargoes.
• In vitro delivery assays using mRNA encoding for firefly luciferase, allowing quantification of translation efficiency post-delivery.
• Comparative delivery of proteins, antibodies, and CRISPR ribonucleoprotein complexes to assess platform versatility.

The authors also explored the mechanism of cellular entry, demonstrating that the molecular motion intrinsic to the IDP-NVs facilitated direct crossing of the plasma membrane, distinct from classical endocytosis pathways.

Core Findings and Why They Matter

The study's principal findings include:

• Stable nanocoacervate formation: IDP-NVs formed robust coacervates with cargos of diverse size, charge, and structure, remaining stable in physiological media.
• Direct cytosolic transport: Nanocoacervates penetrated the cell membrane efficiently, delivering cargos directly into the cytosol without significant endosomal sequestration, as evidenced by live-cell imaging and subcellular fractionation.
• Triggered release: Disassembly of NCs was triggered by cytosolic glutathione, ensuring cargo release only after successful cytosolic delivery.
• Functional outcome: Delivery of mRNA (including firefly luciferase mRNA) resulted in robust protein expression, demonstrating the system's utility in gene regulation reporter assays and mRNA delivery and translation efficiency assay workflows.
• Versatility: The platform enabled efficient delivery of not only mRNA, but also proteins and ribonucleoprotein complexes, underscoring its broad applicability in molecular and cellular biology.

These results collectively establish IDP-NV-based nanocoacervates as a promising platform for intracellular delivery, with clear advantages for assays requiring efficient cytosolic mRNA delivery, such as in vivo bioluminescence imaging and functional genomics.

Comparison with Existing Internal Articles and Contextual Advances

Several recent internal articles have addressed the need for improved mRNA reporter systems and delivery strategies. For instance, the discussion in "Optimizing mRNA Delivery and Reporter Assays with EZ Cap™..." emphasizes the importance of mRNA structure (notably Cap 1) and stability for maximizing luciferase assay sensitivity. This aligns with the reference study's use of optimized mRNA cargos to benchmark delivery efficacy. Additionally, "Raising the Bar: Cap 1 Luciferase mRNA for Translational Immunology" explores how advanced mRNA engineering can minimize innate immune sensing and unlock new applications in translational workflows.

What distinguishes the reference study is its biomimetic delivery mechanism—leveraging IDP-like nanovectors to enable direct cytosolic entry—rather than focusing solely on mRNA design. However, these advances are complementary: the effectiveness of IDP-NV-mediated delivery is maximized when paired with translation-optimized mRNAs (such as Firefly Luciferase mRNA with Cap 1 structure), ensuring both efficient cytosolic access and maximal protein expression. Thus, the study provides a robust delivery framework that synergizes with contemporary bioluminescent reporter for molecular biology platforms.

Limitations and Transferability

Despite its technical advances, the IDP-NV approach faces several limitations. The precise control of nanocoacervate composition and size distribution may pose challenges for reproducibility and scalability beyond laboratory settings. While the study demonstrated efficient delivery in multiple cell types, in vivo validation and safety profiling remain to be fully explored. The long-term effects of repeated nanovector administration and the impact on cellular homeostasis require further investigation. Moreover, while the platform is versatile, its compatibility with clinically relevant large-scale mRNA production and formulation standards has not yet been established.

Protocol Parameters

• Nanocoacervate formation: Mix IDP-NVs with biomacromolecular cargo (e.g., luciferase mRNA) at optimized molar ratios under physiological pH and ionic strength; allow phase separation to proceed at room temperature for 15–30 minutes.
• Cellular delivery: Incubate target cells with freshly prepared nanocoacervates for 2–4 hours; monitor uptake by fluorescence or reporter activity.
• Triggering cytosolic release: Exploit endogenous glutathione levels for intracellular disassembly; no exogenous triggers required.
• Reporter readout: For translation efficiency assays, measure luciferase activity 6–24 hours post-delivery using standard luminescence protocols.
• Workflow suggestion: For maximal mRNA stability, use capped mRNA with Cap 1 structure and optimized poly(A) tail; minimize freeze-thaw cycles and protect from RNase degradation, as recommended in product documentation.

Research Support Resources

To replicate or extend workflows involving direct cytosolic mRNA delivery and sensitive bioluminescent reporter assays, researchers can utilize EZ Cap™ Firefly Luciferase mRNA (SKU R1018) from APExBIO. This in vitro transcribed mRNA incorporates a Cap 1 structure and optimized poly(A) tail, supporting high-efficiency translation and robust luminescent readouts in delivery and gene regulation reporter assay contexts. Its documented stability and translational performance render it well-suited for benchmarking novel delivery vectors, including IDP-NV-based nanocoacervates, as illustrated in the reference study.